Published in Arch Virol on January 01, 1989
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol (1994) 4.40
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol (1995) 3.95
Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol (2004) 3.22
Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A (2003) 3.02
Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol (2000) 2.95
An amphipathic peptide from the C-terminal region of the human immunodeficiency virus envelope glycoprotein causes pore formation in membranes. J Virol (1994) 1.59
Roles of matrix, p2, and N-terminal myristoylation in human immunodeficiency virus type 1 Gag assembly. J Virol (2000) 1.55
Structural analysis of human immunodeficiency virus type 1 Gag protein interactions, using cysteine-specific reagents. J Virol (1996) 1.55
gp160, the envelope glycoprotein of human immunodeficiency virus type 1, is a dimer of 125-kilodalton subunits stabilized through interactions between their gp41 domains. J Virol (1991) 1.45
Characterization of the antibody response specific for the human endogenous retrovirus HTDV/HERV-K. J Virol (1997) 1.37
Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease. J Virol (1997) 1.22
Two types of virus-related particles are found during transmissible gastroenteritis virus morphogenesis. J Virol (1998) 1.21
Cleavage of p15 protein in vitro by human immunodeficiency virus type 1 protease is RNA dependent. J Virol (1994) 1.18
Amino acid sequence analysis of the proteolytic cleavage products of the bovine immunodeficiency virus Gag precursor polypeptide. J Virol (1994) 1.06
Human immunodeficiency virus type 1 gp120 mimics a hidden monomorphic epitope borne by class I major histocompatibility complex heavy chains. J Exp Med (1991) 1.04
Electron cryotomography of ESCRT assemblies and dividing Sulfolobus cells suggests that spiraling filaments are involved in membrane scission. Mol Biol Cell (2013) 1.01
The solution structure of the bovine leukaemia virus matrix protein and similarity with lentiviral matrix proteins. EMBO J (1996) 1.01
Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. J Virol (1999) 0.98
Involvement of human leukocyte antigen class I molecules in human immunodeficiency virus infection of CD4-positive cells. J Virol (1994) 0.97
Constitutive production of nonenveloped human immunodeficiency virus type 1 particles by a mammalian cell line and effects of a protease inhibitor on particle maturation. Antimicrob Agents Chemother (1994) 0.96
DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein. Antimicrob Agents Chemother (1994) 0.84
HSV-2- and HIV-1- permissive cell lines co-infected by HSV-2 and HIV-1 co-replicate HSV-2 and HIV-1 without production of HSV-2/HIV-1 pseudotype particles. Virol J (2007) 0.80
Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells. Clin Exp Immunol (1992) 0.79
Phosphorylation and proteolytic cleavage of gag proteins in budded simian immunodeficiency virus. J Virol (2005) 0.79
An siRNA screen of membrane trafficking genes highlights pathways common to HIV-1 and M-PMV virus assembly and release. PLoS One (2014) 0.75
The SIVmac239 Pr55Gag isoform, SIV p43, suppresses proteolytic cleavage of Pr55Gag. Virology (2006) 0.75
Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology (1987) 7.92
Fatty acid degradation in Escherichia coli. An inducible acyl-CoA synthetase, the mapping of old-mutations, and the isolation of regulatory mutants. Eur J Biochem (1969) 5.58
Application of a fluorogenic PCR assay for typing and subtyping of influenza viruses in respiratory samples. J Clin Microbiol (2000) 3.40
Scrapie infectivity, fibrils and low molecular weight protein. Nature (1984) 3.18
ato Operon: a highly inducible system for acetoacetate and butyrate degradation in Escherichia coli. Eur J Biochem (1972) 2.12
The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy (2008) 1.96
Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis? Lancet (1985) 1.84
Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur J Immunol (1995) 1.78
Gouleako virus isolated from West African mosquitoes constitutes a proposed novel genus in the family Bunyaviridae. J Virol (2011) 1.73
Human-immunodeficiency-virus-type-1-encoded Vpu protein is phosphorylated by casein kinase II. Eur J Biochem (1992) 1.70
Indigenous hepatitis E virus infection of a plasma donor in Germany. Vox Sang (2009) 1.60
The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol (1997) 1.59
A comparative study of the avian reticuloendotheliosis virus: relationship to murine leukemia virus and viruses of the avian sarcoma-leukosis complex. Virology (1975) 1.59
Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A (2004) 1.53
Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer (2000) 1.48
Reported incidence of occupational asthma in France, 1996-99: the ONAP programme. Occup Environ Med (2003) 1.47
Small cell carcinoma of the pleura. A case report. Lung Cancer (1996) 1.47
Antimycoplasma properties and application in cell culture of surfactin, a lipopeptide antibiotic from Bacillus subtilis. Appl Environ Microbiol (1997) 1.45
Migratory pulmonary infiltrates in a patient treated with sotalol. Eur Respir J (1997) 1.45
Salbutamol, terbutaline and pirbuterol allergy in an asthmatic patient. Allergy (2007) 1.42
Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis. Biologicals (1997) 1.42
Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative reference. Clin Chem (1999) 1.35
Human herpesvirus 6A DNA Is detected frequently in plasma but rarely in peripheral blood leukocytes of patients after bone marrow transplantation. J Infect Dis (2000) 1.34
Immunoprecipitation of herpes simplex virus type 1 antigens with different antisera and human cerebrospinal fluids. Arch Virol (1977) 1.30
The organization of the envelope projections on the surface of HIV. Arch Virol (1988) 1.30
Spatial visualization of the maturing HIV-1 core and its linkage to the envelope. AIDS Res Hum Retroviruses (1992) 1.29
Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest (2008) 1.29
Fatty acid degradation in Escherichia coli: requirement of cyclic adenosine monophosphate and cyclic adenosine monophosphate receptor protein for enzyme synthesis. J Bacteriol (1974) 1.26
Detection of human cytomegalovirus DNA by real-time quantitative PCR. J Clin Microbiol (2000) 1.24
Quaternary ammonium compounds and occupational asthma. Int Arch Occup Environ Health (2000) 1.22
Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr (2001) 1.21
Increase of virus yields and releases of Borna disease virus from persistently infected cells. Virus Res (1985) 1.20
Examining landscape factors influencing relative distribution of mosquito genera and frequency of virus infection. Ecohealth (2009) 1.16
Antiviral and hemolytic activities of surfactin isoforms and their methyl ester derivatives. J Antibiot (Tokyo) (1999) 1.16
Hepatitis B and C among Berlin dental personnel: incidence, risk factors, and effectiveness of barrier prevention measures. Epidemiol Infect (2000) 1.15
Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy (2008) 1.12
Determination of the size of HIV using adenovirus type 2 as an internal length marker. J Virol Methods (1994) 1.12
Prediction of mite allergen levels by guanine measurements in house-dust samples. Allergy (1993) 1.10
Epitope mapping of monoclonal antibodies against human immunodeficiency virus type 1 structural proteins by using peptides. J Virol (1989) 1.10
Enterohemolysin production is associated with a temperate bacteriophage in Escherichia coli serogroup O26 strains. J Bacteriol (1990) 1.09
[Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV? Results of a randomized study]. Bull Cancer (1991) 1.08
Capsid symmetry of viruses of the proposed Birnavirus group. Arch Virol (1985) 1.08
Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides. J Gen Virol (1994) 1.06
Characterization of muscarinic receptors in human, guinea pig and rat lung. J Pharmacol Exp Ther (1989) 1.05
Mite allergens: an overview. Eur Ann Allergy Clin Immunol (2011) 1.04
Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil. Braz J Med Biol Res (1999) 1.04
[Occupational asthma: studies and principal etiologic factors]. Bull Eur Physiopathol Respir (1986) 1.04
Bovine herpesvirus 1: differentiation of IBR- and IPV-viruses and identification and functional role of their major immunogenic components. Arch Virol (1985) 1.03
MHC-antigens: constituents of the envelopes of human and simian immunodeficiency viruses. Z Naturforsch C (1988) 1.03
Occupational asthma in France: a 1-yr report of the observatoire National de Asthmes Professionnels project. Eur Respir J (2002) 1.02
Inhibition of viral replication by monoclonal antibodies directed against human immunodeficiency virus gp120. J Gen Virol (1992) 1.02
Monoclonal antibodies directed against human immunodeficiency virus (HIV) gag proteins with specificity for conserved epitopes in HIV-1, HIV-2 and simian immunodeficiency virus. J Gen Virol (1988) 1.01
Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergy. J Allergy Clin Immunol (2000) 1.01
The influence of intramolecular disulfide bonds on the structure and function of Semliki forest virus membrane glycoproteins. Virology (1980) 1.01
Focus-immunoassay for Borna disease virus-specific antigens. Zentralbl Veterinarmed B (1984) 1.00
Effects of cyclic AMP- and cyclic GMP- phosphodiesterase inhibitors on immunological release of histamine and on lung contraction. Br J Pharmacol (1981) 1.00
[Intestinal spirochetosis in HIV infection: prevalence, isolation and morphology of spirochetes]. Dtsch Med Wochenschr (1990) 1.00
The short- and long-term effects of bezafibrate in the rat. Ann N Y Acad Sci (1982) 0.99
HLA class II alleles in isocyanate-induced asthma. Am J Respir Crit Care Med (1994) 0.99
Mechanisms of epithelial barrier impairment in HIV infection. Ann N Y Acad Sci (2000) 0.99
Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol (2001) 0.99
Noninvasive methods for assessment of airway inflammation in occupational settings. Allergy (2009) 0.99
Validation of the sterilization procedure of allogeneic avital bone transplants using peracetic acid-ethanol. Biologicals (2001) 0.98
A double-blind, placebo controlled trial of solidified benzyl benzoate applied in dwellings of asthmatic patients sensitive to mites: clinical efficacy and effect on mite allergens. J Allergy Clin Immunol (1993) 0.98
The functional activity of alpha 1-proteinase inhibitor in bronchoalveolar lavage fluids from healthy human smokers and non-smokers. Clin Chim Acta (1983) 0.98
Increased prevalence of asthma and allied diseases among active adolescent tobacco smokers after controlling for passive smoking exposure. A cause for concern? Clin Exp Allergy (2004) 0.97
The antibody response to the HIV-1 specific "out" (vpu) protein: identification of an immunodominant epitope and correlation of antibody detectability to clinical stages. AIDS Res Hum Retroviruses (1990) 0.97
Fatal poxvirus outbreak in a colony of New World monkeys. Vet Pathol (2006) 0.97
[Endobronchial aspergillosis associated with a carcinoid tumor]. Rev Mal Respir (1990) 0.97
Epithelial uptake and transport of cell-free human immunodeficiency virus type 1 and gp120-coated microparticles. J Virol (1998) 0.95
Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer (1997) 0.95
The cerebrospinal fluid of rabbits infected with Borna disease virus. Arch Virol (1977) 0.95
Sensitivity of HIV antibody detection in saliva. Med Microbiol Immunol (1993) 0.95
Meat wrapper's asthma: identification of the causal agent. Clin Allergy (1980) 0.94
Increased immunoglobulin G production by short term cultured duodenal biopsy samples from HIV infected patients. Gut (1998) 0.94
Medical Indoor Environment Counselor (MIEC): role in compliance with advice on mite allergen avoidance and on mite allergen exposure. Allergy (2003) 0.93
Plaque/focus immunoassay: a simple method for detecting antiviral monoclonal or other antibodies and viral antigens in cells. J Immunol Methods (1984) 0.93
Nerve growth factor levels and localisation in human asthmatic bronchi. Eur Respir J (2002) 0.93
Abnormal predominance of IgG in HIV-specific antibodies produced by short-term cultured duodenal biopsy specimens from HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.93
Conservation of a gene cluster including glycoprotein B in bovine herpesvirus type 2 (BHV-2) and herpes simplex virus type 1 (HSV-1). Virology (1988) 0.92
Comparison of the efficacy of virus inactivation methods in allogeneic avital bone tissue transplants. Cell Tissue Bank (2001) 0.92
Monoclonal antibodies directed against tick-borne encephalitis virus with neutralizing activity in vivo. Acta Virol (1994) 0.92
The structure of the Rous sarcoma virus glycoprotein complex. Arch Virol (1978) 0.92
Transbronchial needle aspiration in the diagnosis of sarcoidosis. Chest (1984) 0.91
Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers. Fundam Clin Pharmacol (2001) 0.91
Monoclonal antibodies against herpes simplex virus type 1-infected nuclei defining and localizing the ICP8 protein, 65K DNA-binding protein and polypeptides of the ICP35 family. J Gen Virol (1988) 0.91
Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy (1999) 0.91
Virus safety in xenotransplantation: first exploratory in vivo studies in small laboratory animals and non-human primates. Transpl Immunol (2002) 0.91
Borna disease virus-specific antigens: two different proteins identified by monoclonal antibodies. Vet Immunol Immunopathol (1991) 0.91
Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology (2000) 0.91
Anaphylactic reactions to formaldehyde in root canal sealant after endodontic treatment: four cases of anaphylactic shock and three of generalized urticaria. Allergy (2003) 0.90
[Prevalence of hantavirus infections in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2004) 0.90
Sequence specific binding of the transcription factor c-Ets1 to the human immunodeficiency virus type I long terminal repeat. Biochem Biophys Res Commun (1993) 0.90
EAACI consensus statement for investigation of work-related asthma in non-specialized centres. Allergy (2012) 0.89
Mapping of immunodominant epitopes of the HIV-1 and HIV-2 integrase proteins by recombinant proteins and synthetic peptides. AIDS Res Hum Retroviruses (1992) 0.89